The abstract is read at the publisher; the summary is JClub's.
Imeglimin preserves mitochondrial membrane potential and normalizes ROS in pancreatic islets under 5% O2, unlike metformin, and improves early graft β-cell mass after intramuscular transplantation.
- Why it matters: Early β-cell loss after islet transplantation is driven by hypoxia-related mitochondrial damage, but imeglimin’s ability to protect islets during this early hypoxic phase was unclear.
- What they did: Islets were exposed to 5% O2 with imeglimin or metformin, with mitochondrial function, ROS, and transcriptomic changes assessed; recipients then received intramuscular islet transplants and were evaluated by glycemic tests and indium-111-labeled exendin-4 imaging on day 14.
- The result: Imeglimin restored Cox6a2 expression and reduced hypoxia-linked YAP/TAZ target signatures, with in vivo imaging showing greater graft β-cell mass on day 14 and histology showing less apoptosis and oxidative stress.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.